Prelude Therapeutics Incorporated Common Stock
PRLD US74065P1012
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 418% | -74% | 3% | 338% | 20% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Combs Andrew SR OFF |
0.69 USD |
100,000 Bought |
69,250 USD |
25/03/2025 | 25/03/2025 |
| Vaddi Krishna CEO |
1.21 USD |
5,000 Bought |
6,044 USD |
31/12/2024 | 31/12/2024 |
| Vaddi Krishna CEO |
1.20 USD |
10,000 Bought |
12,000 USD |
30/12/2024 | 30/12/2024 |
| Combs Andrew SR OFF |
1.37 USD |
60,000 Bought |
82,002 USD |
20/12/2024 | 23/12/2024 |
| Combs Andrew SR OFF |
1.15 USD |
3,075 Bought |
3,536 USD |
20/12/2024 | 20/12/2024 |
| Vaddi Krishna CEO |
0.89 USD |
6,888 Bought |
6,116 USD |
18/12/2024 | 19/12/2024 |
| Lim Bryant David CLO |
0.91 USD |
25,000 Bought |
22,638 USD |
19/12/2024 | 19/12/2024 |
| Vaddi Krishna CEO |
0.93 USD |
100,000 Bought |
93,210 USD |
18/12/2024 | 18/12/2024 |